Healthcare
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from March 31st to December 31st Announced revenue guidance of $8 million for the year ending December 31, 2026 which represents approximately 15% growth; and $16-$18 million or more than 110% growth for the year ending December 31, 2027 Conference call at 8:00 a.m. ET today, June 26th GARDEN CITY, N.Y., Ju
About this update from Beyond Air, Inc.
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from March 31st to December 31st Announced revenue guidance of $8 million for the year ending December 31, 2026 which represents approximately 15% growth; and $16-$18 million or more than 110% growth for the year ending December 31, 2027 Conference call at 8:00 a.m. ET today, June 26th GARDEN CITY, N.Y., June 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced its financial results for the fiscal fourth quarter and year ended March 31, 2026, and provided a corporate update. "Fiscal 2026 was a year of meaningful transition for Beyond Air, marked by significant progress in strengthening the foundation of our LungFit PH commercial program," said Robert Goodman, Chief Executive Officer of Beyond Air. "Since being appointed CEO, I have focused on sharpening our commercial execution while aligning our R&D efforts and operating resources with the opportunities we believe can create the greatest shareholder value. Our fiscal 2026 performance, including the 107% revenue growth, strong customer retention of over 90% and new hospital customer wins, reflect that focus and positions us for what we believe could be an important inflection point for the business." "We are encouraged by the market interest in the second-generation LungFit PH system, which is currently under FDA review," continued Mr. Goodman. "Subject to FDA approval, the system is designed to provide a smaller footprint, reduced weight, simplified operation, longer service intervals and expanded operational flexibility. The PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground. If approved, we believe the addressable market opportunity for the LungFit platform could increase by 4X in the United States to approximately $400 million, and to more than $1 billion worldwide," concluded Mr. Goodman. Recent Financial and Operating Highlights: